Table S7. SwissADME results of the synthesized pyrazine-thiazole analogues.

NO	M. Wt.	HBA	HBD	TPSA	MiLOGP	ESOL Class	GI Absorpn.	BBB permeant	Pgp substrate	Lipinski violations	Bioavailability Score
2	462.28	6	2	157.51	1.98	Soluble	High	No	No	0	0.55
3	474.51	7	1	190.17	2.49	Soluble	High	No	No	0	0.55
4a	489.49	8	1	226.76	1.85	Soluble	High	No	No	1	0.55
4b	478.93	6	1	180.94	2.44	Soluble	High	No	No	0	0.55
4c	521.57	8	1	192.68	3.14	Soluble	High	No	No	1	0.55
6a	536.54	9	1	229.27	2.45	Moderate	High	No	No	2	0.17
6b	525.99	7	1	183.45	3.05	Moderate	Low	No	No	1	0.55
6c	492.53	7	2	209.47	2.08	Moderate	Low	No	No	0	0.55
8a	507.5	8	2	246.06	1.4	Moderate	High	No	No	2	0.55
8b	496.95	6	2	200.24	2.45	Moderate	High	No	No	0	0.55
9	425.48	6	2	166.44	2.51	Moderate	High	No	No	0	0.55
11a	440.46	7	2	203.03	1.74	Poor	Low	No	No	0	0.55
11b	429.9	5	2	157.21	2.52	Poor	Low	No	No	1	0.55
11c	462.96	6	2	128.05	3.55	Poor	Low	No	No	0	0.55

M. Wt.: molecular weight, M iLog P: lipophilicity parameter, HBA: hydrogen bond acceptor, HBD: hydrogen bond donor, TPSA: topological polar surface area.